Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients

被引:59
|
作者
Willemsen, Suzan [1 ]
Hartog, Jasper W. L. [1 ]
Hummel, Yoran M. [1 ]
van Ruijven, Marieke H. I. [1 ]
van der Horst, Iwan C. C. [1 ]
van Veldhuisen, Dirk J. [1 ]
Voors, Adriaan A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 RB Groningen, Netherlands
关键词
Heart failure; Diastolic function; Diabetes; Advanced glycation end products; VENTRICULAR EJECTION FRACTION; RISK-FACTORS; CONSEQUENCES; MELLITUS; STRESS;
D O I
10.1093/eurjhf/hfq168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Advanced glycation end products (AGEs) are increased in patients with diabetes and are associated with diastolic dysfunction through the formation of collagen crosslinks in the heart. The association among AGEs, diastolic function, and aerobic capacity in heart failure (HF) patients with and without diabetes is, however, unknown. We therefore studied the association among tissue AGEs, diastolic function, and aerobic capacity in patients with HF with or without diabetes. Methods and results In chronic HF patients (with and without left ventricular systolic dysfunction), tissue AGEs [skin autofluorescence (AF)], diastolic function (echocardiographic mean E' and E/E'), and aerobic capacity [peak oxygen uptake (VO2) on cardiopulmonary exercise testing] were obtained. A total of 49 diabetics and 156 non-diabetics were included. Diabetics were older and had more cardiovascular risk factors, but left ventricular ejection fractions (LVEF) were similar. Tissue AGEs were higher in diabetics compared with non-diabetics (2.8 +/- 0.8 vs. 2.3 +/- 0.7 a.u.; P < 0.001). Furthermore, there was a correlation between tissue AGEs and mean E' (r = -0.30; P < 0.001, after adjustment for age, r = -0.21; P = 0.004). Aerobic capacity was significantly lower in diabetic patients with HF (peak VO2: 17.4 +/- 5.1 vs. 21.7 +/- 6.1 mL/min/kg; P = 0.001), even after adjustment for age and LVEF. Peak VO2 was related to skin AF (P = 0.03), independent of age, diabetes, LVEF, and New York Heart Association functional class. Conclusion Patients with diabetes and HF have similar LVEF but poorer exercise capacity compared with non-diabetic HF patients. Our data suggest that these findings might be explained by the observed association among tissue AGE levels, diastolic function, and exercise capacity.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [21] Exercise training improves aerobic capacity in elderly patients with diastolic heart failure: A randomized, controlled trial
    Kitzman, DW
    Brubaker, PH
    Anderson, RT
    Morgan, T
    Miller, HS
    Stewart, KP
    Ettinger, W
    Hundley, WG
    CIRCULATION, 1999, 100 (18) : 296 - 296
  • [22] Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients
    Choi, EY
    Kwon, HM
    Ahn, CW
    Lee, GT
    Joung, BY
    Hong, BK
    Yoon, YW
    Kim, DS
    Byun, KH
    Kang, TS
    Yoon, SJ
    Kwon, SW
    Lee, SJ
    Park, JW
    Kim, HS
    YONSEI MEDICAL JOURNAL, 2005, 46 (01) : 78 - 85
  • [23] Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients
    Choi, EY
    Kwon, HM
    Kim, D
    Yoon, YW
    Jung, B
    Kim, HS
    Ahn, CW
    Byun, KH
    CIRCULATION, 2004, 110 (17) : 488 - 489
  • [24] Relationship of diastolic intraventricular pressure gradients and aerobic capacity in patients with diastolic heart failure
    Rovner, A
    Greenberg, NL
    Thomas, JD
    Garcia, MJ
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 289 (05): : H2081 - H2088
  • [25] Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study
    Arshi, Banafsheh
    Chen, Jinluan
    Ikram, M. Arfan
    Zillikens, M. Carola
    Kavousi, Maryam
    DIABETOLOGIA, 2023, 66 (03) : 472 - 481
  • [26] Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study
    Banafsheh Arshi
    Jinluan Chen
    M. Arfan Ikram
    M. Carola Zillikens
    Maryam Kavousi
    Diabetologia, 2023, 66 : 472 - 481
  • [27] ADVANCED GLYCATION END PRODUCTS AND GLYCOSAMINOGLYCAN LEVELS IN PATIENTS WITH DIABETIC KETOACIDOSIS
    Edriss, H.
    Selvan, K.
    Quezada, R. E. Gavidia
    Molehin, A.
    Nugent, K.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 613 - 613
  • [28] Improvements in diastolic function among patients with advanced systolic heart failure utilizing Alagebrium (an oral advanced glycation end-product crosslink breaker)
    Thohan, V
    Koerner, MM
    Pratt, CM
    CIRCULATION, 2005, 112 (17) : U620 - U620
  • [29] Advanced glycation end products in senile diabetic and nondiabetic patients with cataract
    Gul, Anjuman
    Rahman, Muhammad Ataur
    Salim, Asmat
    Simjee, Shabana U.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2009, 23 (05) : 343 - 348
  • [30] Expression of advanced glycation end products and their receptors in diabetic periodontitis patients
    Thomas, Julie Toby
    Joseph, Betsy
    Sorsa, Timo
    Mauramo, Matti
    Anil, Sukumaran
    Waltimo, Tuomas
    ORAL DISEASES, 2024, 30 (05) : 2784 - 2796